Skip to main content
MedinCell S.A. logo

MedinCell S.A. — Investor Relations & Filings

Ticker · MEDCL ISIN · FR0004065605 LEI · 969500R79U6PXCL2FF46 PA Manufacturing
Open in API
Filings indexed 522 across all filing types
Latest filing 2020-01-13 Regulatory Filings
Country FR France
Listing PA MEDCL

About MedinCell S.A.

https://www.medincell.com/en/

MedinCell S.A. is a pharmaceutical company at the commercial stage that specializes in the development of long-acting injectable (LAI) therapies. The company's core is its proprietary BEPO® technology platform, which enables the controlled and sustained release of active pharmaceutical ingredients over periods ranging from days to months after a single injection. This technology forms a fully biodegradable depot in situ, designed to improve treatment efficiency, enhance patient compliance, and increase the global accessibility of medicines. MedinCell develops a portfolio of LAI products across various therapeutic areas, including psychiatry, advancing its pipeline through both internal research and strategic partnerships with other pharmaceutical organizations.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Regulatory Filings Classification · 99% confidence The document is titled "MedinCell provides a portfolio update for J.P. Morgan Healthcare Conference 2020" and is dated January 13, 2020. It details the status of various drug development programs (clinical stage, preclinical stage, formulation stage) and references past press releases. This content structure—a company providing an update on its pipeline, often coinciding with an industry event like a healthcare conference—is characteristic of an Investor Presentation (IP) or a high-level summary intended for investors. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). Since it is a detailed presentation of strategy and pipeline progress aimed at investors, 'Investor Presentation' (IP) is the most appropriate classification.
2020-01-13 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 99% confidence The document is titled with an announcement regarding MedinCell's product portfolio update presented at the J.P Morgan Healthcare 2020 conference. It details clinical trial statuses (Phase 3, Phase 1, pre-clinical), partnership updates, and future milestones (e.g., intermediate analysis in H2 2020). It is dated January 13, 2020, and explicitly states it is a 'communiqué de presse' (press release). This content structure—providing key operational and pipeline updates, often timed around major industry events—is characteristic of an Earnings Release (ER) or a general Investor Presentation (IP). Since it focuses on pipeline progress and future expectations rather than a comprehensive review of past financial performance (like an IR or 10-K), and it is presented as a formal announcement, it aligns best with an Earnings Release (ER) which often includes operational highlights, or potentially an Investor Presentation (IP) if it were structured as slides. Given the format is a press release summarizing operational progress and future outlook, ER is the most appropriate fit among the choices, as it communicates key periodic business updates, even if not strictly quarterly financials. It is not a transcript (CT), a formal annual report (10-K), or a simple announcement of a report being published (RPA/RNS).
2020-01-13 French
Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité
Share Issue/Capital Change Classification · 99% confidence The document is titled "Bilan semestriel du contrat de liquidité" (Semi-annual statement of the liquidity contract) and reports on the status and transactions under a liquidity contract (market making agreement) as of December 31, 2019, comparing it to the previous period (June 30, 2019). This type of report details the management of company shares for market stability, which falls under corporate financing or capital structure activities. While it is a periodic report, it is not a comprehensive financial report (10-K or IR). It specifically details actions related to share capital management and market operations, which aligns best with 'Capital/Financing Update' (CAP) or potentially a specialized regulatory filing. Given the focus on the liquidity contract (share trading/stabilization), 'CAP' is the most appropriate fit among the provided options, as it relates directly to capital structure management and financing mechanisms. It is a specific report, not an announcement of a report's publication.
2020-01-09 French
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information mensuelle relative au nombre d'actions composant le capital social et au nombre total des droits de vote" (Monthly information relating to the number of shares comprising the share capital and the total number of voting rights), dated December 12, 2019, and references Article 223-16 of the AMF General Regulation. It explicitly provides a table showing the number of shares and voting rights as of November 30, 2019. This content directly relates to changes in share capital and voting rights, which aligns with the definition of a Major Shareholding Notification (MRQ) or potentially a Share Issue/Capital Change (SHA). However, the specific focus on the monthly calculation of total voting rights and share capital, often required for regulatory disclosure regarding ownership thresholds, strongly points towards a notification related to significant shareholdings or capital structure updates. Since it is a monthly update on the total number of shares and voting rights, it is most closely related to tracking ownership changes or capital structure disclosure. Given the options, 'Major Shareholding Notification' (MRQ) is the closest fit for regular disclosures concerning the total capital structure and voting rights, although 'Share Issue/Capital Change' (SHA) is also relevant. Since this is a routine monthly disclosure of the total capital base and voting rights, and not an announcement of a specific transaction (like a buyback or new issue), MRQ, which covers changes in significant ownership levels (often triggered by these totals), is a reasonable classification, or alternatively, SHA for capital structure reporting. Given the explicit focus on the *total* number of shares and voting rights as a regulatory requirement, SHA (Share Issue/Capital Change) is a strong candidate as it covers capital structure reporting. However, in many regulatory contexts, these monthly voting rights disclosures are filed when thresholds are crossed, making MRQ applicable. Let's re-evaluate the definitions. SHA is for *announcement regarding new share issues, stock splits, or other capital changes*. MRQ is for *Notification of changes in significant share ownership levels (crossing thresholds)*. Since this document reports the *current total* as of a specific date, it serves as the basis for threshold monitoring. In the context of French regulations (AMF), these monthly reports are standard disclosures related to the total capital base. SHA seems slightly more appropriate as it reports on the capital structure itself, even if it's a routine update, rather than focusing solely on a specific shareholder crossing a threshold (MRQ). Given the content is a direct report on the capital structure components (shares and votes), SHA is selected as the primary fit for capital structure reporting, although it is a borderline case with MRQ/RNS. I will classify it as SHA based on the direct reporting of the capital structure components.
2019-12-12 French
Rapports financiers et d'audit semestriels/examens réduits / Rapport financier semestriel
Interim / Quarterly Report Classification · 100% confidence The document is titled 'RAPPORT FINANCIER SEMESTRIEL' (Semi-annual Financial Report) for the period from April 1 to September 30, 2019. It contains a detailed summary, management activity report, consolidated financial statements, and an audit review report. This fits the definition of an Interim/Quarterly Report (IR) as it provides comprehensive financial data and analysis for a period shorter than a full fiscal year. H2 2019
2019-12-04 French
Inside Information / News release on accounts, results
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the first half-year (April-September 2019) of MedinCell. It contains detailed financial statements, including a consolidated cash flow statement and a consolidated income statement, along with management's analysis of the financial results, business trends, and operational highlights. Since it provides substantive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H2 2019
2019-12-03 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.